| Metric | Q3 2026 | Q3 2025 |
|---|---|---|
| Revenue | 1.3 | 2.6 |
| Profit before tax | -5.5 | -8.4 |
| Net income | -2.9 | -6.4 |
| EPS (diluted, $ a share) | $-0.04 | $-0.09 |
A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.
| Revenue, year on year | -49.7% |
|---|---|
| Operating margin | -495.1% |
10-Q filed with the SEC, NASDAQ: SIGA. Figures from the filing's XBRL data; summary written with AI assistance from the filing.
Siga Technologies Inc: key numbers
- Share price
- $2.85Close, Nov 16
- Market cap
- $205M
- Shares outstanding
- 71.86MLatest SEC cover page
- Sector
- Life Sciences
- Industry
- Pharmaceutical PreparationsSIC 2834
Today's reference numbers, updated daily. Not a valuation or a recommendation.
More from Siga Technologies Inc
All →Siga Technologies Financial Results
SIGA Technologies reported financial results for the third quarter ended September 30, 2026, showing total revenues of $1.3 million and a net loss of $2.9 million. The company highlighted a new $15 million procurement contract with the Canadian Department of National Defence for oral TPOXX and the retirement of its Chief Scientific Officer, Dr. Dennis Hruby.
“While we continue to work with the U.S. Government toward a new TPOXX procurement contract, our international business remains an important part of our strategy. We recently announced a $15 million contract with the Canadian Department of National Defence, a longstanding customer, and are actively pursuing opportunities with other international governments to further diversify our customer base over time.”
Diem Nguyen, Chief Executive Officer